Research programme: Brain disorders therapeutics - Ildong Pharmaceuticals
Latest Information Update: 31 Aug 2023
At a glance
- Originator Ildong Pharmaceutical
- Class
- Mechanism of Action Amyloid precursor protein secretase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Brain disorders
Most Recent Events
- 31 Aug 2023 NDR Batch #29- Development discontinued as it is not listed on company website. Intro, KDM, DevT, HE updated
- 31 Aug 2023 Discontinued - Preclinical for Brain disorders in South Korea (unspecified route)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Brain-disorders in South Korea